AstraZeneca reorg to cut 1,600 jobs in US, UK
In this Jan. 29, 2009 file photo, reflections are seen on a sign outside the global headquarters of AstraZeneca in London. Struggling Anglo-Swedish drugmaker AstraZeneca PLC said Monday, March 18, 2013, that it will eliminate 1,600 jobs, mostly in the U.S. and United Kingdom, as its new CEO starts a major research and development reorganization. Even the global headquarters will be shifted, from London to Cambridge, England, as the company moves many of its scientists near top centers for bioscience research. (AP Photo/Kirsty Wigglesworth, File)
(AP)—Struggling Anglo-Swedish drugmaker AstraZeneca PLC said Monday that it will eliminate 1,600 jobs, mostly in the U.S. and United Kingdom, as its new CEO starts a major research and development reorganization.
The cuts, meant to reduce costs and make research programs more productive, come just weeks after the company reported big drops in revenue and net income for 2012 and forecast continuing difficulties as generic competition hurts sales.
The job reductions amount to nearly 3 percent of AstraZeneca's 57,200 workers worldwide and are part of moves affecting several major AstraZeneca sites in the UK, U.S. and Sweden.
Even the global headquarters will be shifted, from London to Cambridge, England, as the company moves many of its scientists near top centers for bioscience research. Rivals have been doing the same, to be near those talent pools and to increase collaborations with scientists at universities and small biotech companies.
The changes, to be made between now and 2016, are expected to produce annual savings of about $190 million by then. They'll result in restructuring charges of $1.4 billion, about $800 million of that likely in cash.
"Given the limited financial benefits, this deal is really about improving science, and the ability to capture innovation and recruit top-tier scientists," Citigroup analyst Mark Dainty wrote to investors. "The pay-off is likely to take several years to be realized but is evidence of sensible organizational change, in our view."
In the U.S., AstraZeneca will scale back its site in Wilmington, Delaware, by about 1,200 jobs. That includes eliminating 650 positions and shifting 300 others as key functions are transferred to Gaithersburg, Maryland, home to AstraZeneca's MedImmune subsidiary and research on biologic drugs—injected medicines produced in living cells rather than by mixing chemicals.
AstraZeneca's global medicines development group, which oversees research on both pills and injectable biologic drugs, will move from Wilmington to Gaithersburg, as will the global marketing staff and U.S. sales staff for specialty drugs. Those are complex, very expensive injected medicines for chronic conditions.
Wilmington will still be AstraZeneca's North American headquarters for sales and marketing, with about 2,000 employees remaining. The other 250 jobs being cut in Wilmington include 80 going to a site in Waltham, Massachusetts, and about 170 going to other U.S. or overseas locations.
In the UK, AstraZeneca said most of the corporate and global commercial functions based in London will move to a new $500 million center being built in Cambridge. The company will consolidate all its UK pill and biologic drug research in Cambridge, which is known for innovation in the biological sciences and links to key research institutions in London.
"This is a major investment in the future of this company that will enable us to accelerate innovation by improving collaboration, reducing complexity and speeding up decision-making," CEO Pascal Soriot, who took over last August after his predecessor resigned, said in a statement. "The strategic centers will also allow us to tap into important bioscience hotspots."
The company said its site in Molndal, Sweden, will join Cambridge and Gaithersburg as one of its three strategic centers, focusing on developing traditional drugs in pill form.
The three sites will be supported by other AstraZeneca facilities around the world, including the one in Waltham.
Meanwhile, AstraZeneca will end research and development work at its facility at Alderly Park in the UK. It will move about 1,600 jobs from there to a nearby manufacturing facility in Macclesfield, the new center in Cambridge or company sites overseas. The company said at least 700 nonresearch jobs will remain at Alderly Park, and it will explore options for "a successful future" for that facility.
Like other big drugmakers, AstraZeneca is being squeezed by the weak global economy, government health programs trying to hold down spending, rising research costs and a surge of new generic competition to blockbuster drugs that had brought in billions every year.
In January, AstraZeneca said generic competition in Western Europe and other areas was slashing sales of top sellers including Nexium for severe heartburn, Seroquel IR for schizophrenia and Crestor for high cholesterol. The company's total sales dropped to $28 billion last year, from $33.6 billion in 2011, while net income plunged 37 percent.
So like most of its rivals, AstraZeneca is trying to do more with less staff and improve its success rate in the laboratory and in the expensive patient testing needed to get new drugs approved. The process generally takes a decade or more and costs more than $1 billion per drug, averaging in the costs for hundreds of failed drug candidates.
In early-afternoon U.S. trading, AstraZeneca shares were down 22 cents at $46.24.
Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
- AstaZeneca in patent warning as net profit falls Jan 31, 2013 | not rated yet | 0
- Abbott, AstraZeneca seek cholesterol pill approval Jun 04, 2009 | not rated yet | 0
- EU steps up generic pharma anti-trust probe Dec 03, 2010 | not rated yet | 0
- Bristol-Myers gets EU approval for diabetes drug Oct 05, 2009 | not rated yet | 0
- AstraZeneca, Merck collaborate on cancer treatment Jun 01, 2009 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013 Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.
Medications 10 hours ago | 1 / 5 (1) | 0
(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...
Medications 11 hours ago | 5 / 5 (1) | 0
An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.
Medications May 22, 2013 | not rated yet | 0
GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.
Medications May 22, 2013 | not rated yet | 0
The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...
Medications May 22, 2013 | not rated yet | 0
(Medical Xpress)—Regulating the distribution of power in neurons is done by a system that makes the national electric grid look simple by comparison. Each neuron has several thousand mitochondria confined ...
10 hours ago | 4.8 / 5 (5) | 0 |
A brief visual task can predict IQ, according to a new study. This surprisingly simple exercise measures the brain's unconscious ability to filter out visual movement. The study shows that individuals whose ...
16 hours ago | 4.5 / 5 (10) | 1 |
Teams of highly respected Alzheimer's researchers failed to replicate what appeared to be breakthrough results for the treatment of this brain disease when they were published last year in the journal Science.
14 hours ago | 5 / 5 (1) | 2 |
Scientists at the National Institutes of Health report they have discovered in mouse studies that a small molecule released in the spinal cord triggers a process that is later experienced in the brain as ...
14 hours ago | 5 / 5 (2) | 0 |
Little is known about why asthma develops, how it constricts the airway or why response to treatments varies between patients. Now, a team of researchers at Weill Cornell Medical College, Columbia University Medical Center ...
14 hours ago | not rated yet | 0 |
Ethnic background plays a surprisingly large role in how diabetes develops on a cellular level, according to two new studies led by researchers at the Stanford University School of Medicine.
12 hours ago | not rated yet | 0 |